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Abstract
Objective: To identify opportunities to reduce overuse of antibiotics for prevention of perinatal group B streptococcal
(GBS) disease and management of preterm premature rupture of membranes (pPROM).
Methods: An anonymous written questionnaire was sent to each of 1031 Fellows of the American College of Obstetricians
and Gynecologists, and the responses were subjected to statistical analysis.
Results: Among those of the 404 respondents who saw obstetric patients in 2001, most (84%) screened for GBS
colonization, and 22% of these prescribed prenatal antibiotics to try to eradicate GBS colonization. Of the 382 respondents
(95%) who prescribed antibiotics for pPROM, 36% continued antibiotics for more than 7 days despite negative results from
GBS cultures collected before initiation of treatment. Having more years of clinical experience (adjusted odds ratio (OR)
3.0, 95% conﬁdence interval (CI) 1.5 to 6.2), working in a non-academic setting (adjusted OR 2.7, 95% CI 1.0 to 6.9), and
prescribing antibiotics prenatally for GBS colonization (adjusted OR 2.0, 95% CI 1.1 to 3.4) were associated with
prescribing prolonged antibiotics for pPROM.
Conclusion: Prenatal antibiotic treatment for GBS colonization and prolonged antibiotic treatment for pPROM contribute
to overuse of antibiotics in obstetrics.
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Introduction
Prophylactic use of antimicrobials can play an
important role in improving pregnancy outcomes.
For example, widespread use of intrapartum anti-
microbial prophylaxis for prevention of perinatal
group B streptococcal (GBS) disease in the USA led
to a 70% decline in a leading infectious cause of
neonatal mortality [1, 2]. Prophylactic antibiotics
may also promote beneﬁcial outcomes among
women with preterm premature rupture of the fetal
membranes (pPROM), either by prolonging the
latency of the pregnancy [3–9] or by preventing
adverse neonatal and maternal outcomes due to
infectious causes [7, 10].
However, use of prophylactic antibiotics is not
always appropriate. Prenatal prophylaxis to eradicate
GBS colonization before the intrapartum period has
never been recommended, because early studies
demonstrated that eradication was rarely achieved
or maintained [11, 12]. Provider practices regarding
prenatal prophylaxis, however, have not been char-
acterized. Because current prevention guidelines
recommend late antenatal culture-based screening
for all pregnant women, prenatal prophylaxis for
colonized women could lead to substantial overuse of
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obstetric practice [2, 13, 14].
For the case of preterm delivery, prophylactic
antibiotic recommendations are more complex.
From the narrow perspective of GBS prevention,
guidelines are most clear. Because preterm delivery
is associated with an increased risk of neonatal GBS
disease, all women with unknown or positive GBS
status who present in preterm labor should receive
GBS intrapartum prophylaxis. To avoid overuse of
antibiotics, women of unknown GBS colonization
status should be tested for GBS before initiating
prophylaxis; GBS prophylaxis should be stopped for
women who are subsequently found to have negative
culture results [2].
From the broader perspective of preventing
adverse outcomes of pPROM, however, antibiotic
prophylaxis is supported in some cases even in
women known to be GBS-negative. ACOG’s
practice guidelines for the clinical management of
pPROM from 1998 recommend antibiotic use with
expectant management [15]. Antimicrobial regi-
mens are primarily 7-day courses and include
agents such as ampicillin and erythromycin or co-
amoxiclav (amoxicillin/clavulanic acid) [15]. These
guidelines, based on the best evidence available at
the time, were motivated in part by an inﬂuential
randomized controlled multicenter trial [16] of
women with pPROM that found multiple beneﬁts
of antibiotic treatment, including fewer cases of
neonatal respiratory distress and necrotizing enter-
ocolitis. However, this trial only enrolled women
with pPROM remote from term (24 to 32 weeks’
gestation) and did not allow the use of corticoster-
oids, factors which both inﬂuence the effect of
antibiotics on improving pPROM outcomes. A
recent large prospective randomized controlled trial
that enrolled women of any gestational age 537
weeks, and treated more than 75% of subjects with
steroids, did not fully support earlier results [17].
Use of erythromycin was associated with limited
maternal and neonatal beneﬁts, including pro-
longed latency and reduced neonatal morbidity.
Use of co-amoxiclav, however, was associated with
increased risks of necrotizing enterocolitis and
therefore not recommended despite prolonging
latency slightly [17].
In the light of these newer concerns about adverse
consequences of antibiotics, as well as growing
concerns about emerging antimicrobial resistance
among pathogens affecting preterm infants [18], an
ACOG Practice Bulletin on intrapartum prophylaxis
[19] recommends that providers consider antibiotic
prophylaxis for pPROM on an individual patient
basis and stresses that antibiotics are most beneﬁcial
for cases of extreme prematurity where prolongation
of latency is the primary objective. This statement,
which came out after our survey was completed, does
not replace the 1998 pPROM guidelines; it also does
not deﬁne extreme prematurity or provide detailed
management guidance.
Although antibiotic prophylaxis in the obstetric
setting can greatly reduce morbidity and mortality,
unnecessary use of antibiotics has the potential to
harm both the mother and newborn, and in some
circumstances may also adversely affect the commu-
nity by increasing risk of antimicrobial resistance. We
conducted a national survey of obstetrician-gynecol-
ogists to characterize antibiotic prescription practices
related to perinatal GBS disease prevention and
management ofpPROM,toevaluatecompliancewith
current recommendations, and to identify opportu-
nities to reduce overuse of prophylactic antibiotics.
Methods
In June 2002, an anonymous questionnaire was sent
to 1031 ACOG Fellows, comprising 409 Fellows in
the Collaborative Ambulatory Research Network
(CARN: a group of volunteers established in 1990
which helps ACOG monitor provider practices by
participating in roughly four surveys per year), and
622 randomly selected non-CARN Fellows. Those
who did not respond received a second mailing
approximately 6 weeks later. The study protocol was
considered by an Institutional Review Board at the
Centers for Disease Control and Prevention and
designated exempt from the need for formal human
subjects review.
The survey, which aimed to assess antibiotic
prescribing practices of obstetrician-gynecologists
both in perinatal care and for upper respiratory
tract infections (URTIs), included predominantly
multiple choice questions about respondents’ demo-
graphics, practice settings and patient populations.
Questions related to antibiotic use for GBS disease
prevention and pPROM were primarily in a scale
format (always/sometimes/never) and included:
(1) Do you screen your obstetric patients for
vaginorectal group B streptococcal (GBS)
colonization?
(2) If you ﬁnd GBS vaginorectal colonization in an
obstetric patient, how often do you prescribe
prenatal antibiotics to attempt to eradicate
colonization (not bacteriuria)?
(3) (3a) In a woman with preterm rupture of
membranes but no fever, uterine tenderness
or signs of imminent delivery, how often do you
prescribe antibiotics?
(4) (3b) If the GBS culture is negative in the
situation described above, how often do you
continue antibiotics beyond one week after
the onset of preterm rupture of membranes?
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you continue antibiotics with a negative GBS
culture (or no culture), what is the usual reason
for continuing antibiotics?
(6) (3d) Which agent(s) do you commonly pre-
scribe for preterm rupture of membranes (orally
or IV or both) in the above situation?
These last two questions (3c and 3d) asked
respondents to check all answers that applied. The
rest of the survey, which consisted of questions about
antibiotic prescribing practices for URTIs, was
analyzed separately [20].
To assess the current practices of providers we
excluded individuals enrolled in training programs or
who saw no obstetric patients in 2001. Survey
responses were double-entered. Statistical analysis
was performed using SAS version 9.0 (SAS Institute,
Cary, NC, USA). Continuous variables (clinical
experience and proportion of pregnant patients seen)
were categorized by quartiles. Answers to questions
using an always/sometimes/never format were con-
densed to the categories ever/never for analysis
purposes. Univariate associations were evaluated
using the chi-square test for categorical variables
and the Wilcoxon rank sum test for continuous
variables; signiﬁcance was assessed using Mantel–
Haenszel–Cochran summary odds ratios (ORs) and
95% conﬁdence intervals (CIs). Independent vari-
ables that were evaluated included gender, CARN
status, years of clinical experience, location and type
of practice, proportion of pregnant patients seen, and
prescription of antibiotics for the common cold.
CARN status, gender, years of clinical experience
and all variables signiﬁcant at p50.15 in univariate
analysis were evaluated in multivariable models using
stepwise logistic regression. Because the CARN
group differed from the non-CARN group in
response rate and demographics (see below), all
multivariable models controlled for CARN status.
The ﬁnal multivariable model contained all main
effects signiﬁcant at p50.05. All two-way interac-
tions of main effects were evaluated.
Results
Of 1031 mailed surveys, 519 were returned for an
overall response rate of 50%; the response rate for
the CARN group was higher than for non-CARN
Fellows (65% versus 41%, p50.001). Of these
519 respondents, 97 were excluded because they
did not see obstetric patients, and 18 were
excluded for other reasons; 404 (215 CARN and
189 non-CARN) were eligible for inclusion in the
analysis. The CARN and non-CARN groups did
not differ signiﬁcantly for a majority of character-
istics. Respondents had a median of 15 years of
clinical experience, and 56% were men. The
CARN group had more years of clinical experience
than the non-CARN group (median years experi-
ence 16 versus 10, p50.001).
A high proportion of respondents (84%) screened
obstetric patients for GBS colonization. In our study,
the proportion of respondents that performed pre-
natal GBS screening was signiﬁcantly higher among
both groups than in 1999, when an earlier survey of
ACOG members was conducted [21]. In this earlier
1999 survey, 70% of the CARN group screened for
GBS in obstetric patients (versus 86% in 2001,
p50.001), and 70% of the non-CARN group
screened (versus 84% in 2001, p50.001). Providers
who screened in 2001 did not differ signiﬁcantly
from those who did not by demographic character-
istics, practice type or practice location. However,
those whose practice served more than 25% obstetric
patients were more likely to screen for GBS
colonization (adjusted OR 2.5, 95% CI 1.4 to 5).
Among respondents who performed antenatal
GBS screening, nearly one in four (22%) prescribed
prenatal antibiotics sometimes (9%) or always (13%),
in an attempt to eradicate GBS colonization. Factors
associated with prescribing prenatal antibiotics for
GBS colonization are shown in Table I. In multi-
variable analysis, prolonged use of antibiotics for
pPROM (adjusted OR 2.4, 95% CI 1.3 to 4.5) and
prescribing antibiotics for the common cold (adjusted
OR 2.0, 95% CI 1.1 to 3.8) were signiﬁcantly
associated with prescribing prenatal antibiotics in an
attempt to eradicate GBS colonization.
Almost all respondents (95%) prescribed antibio-
tics for women with pPROM; 75% of the prescribers
reported always prescribing antibiotics in this situa-
tion. Those who never prescribed antibiotics were
more likely to work in small practices (adjusted OR
2.7, 95% CI 1.1 to 6.8). Among the 369 respondents
who reported screening for GBS and prescribing
antibiotics for pPROM, 134 (36%) reported con-
tinuing antibiotics for more than 7 days for GBS-
negative women with pPROM and no signs of
clinical infection. Of these, common reasons for
prolonged antibiotic use included empiric treatment
of chorioamnionitis (30%), prolongation of the
pregnancy (7%), or both (39%). Mistrust of GBS
culture was never the sole reason for continuing
therapy beyond 7 days, but was reported by 24% as
one of the reasons for continued therapy. A majority
of respondents (55%) prescribed multiple agents for
prolonged courses. The most common agents
included ampicillin (84% or 113 of 134) and
erythromycin (29% or 39 of 134); 7 % (10 of 134)
used amoxicillin clavulanate.
Providers who continued antibiotics for more than
7 days for GBS-negative women with pPROM were
more likely to be men, to have more years of clinical
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and, to prescribe prenatal antibiotics in an attempt to
eradicate GBS colonization (Table II). In multi-
variable analysis, predictors of prolonged antibiotic
therapy included being a non-CARN member,
having more clinical experience, working in a non-
academic setting, and prescribing antibiotics prena-
tally to eradicate GBS colonization.
Discussion
Our ﬁnding that nearly a quarter of all respondents
who screened for GBS colonization prescribed
antibiotics prenatally in an attempt to eradicate
GBS colonization documents an important overuse
of antibiotics that is of even more concern now that
universal GBS screening is recommended. Since the
release of the ﬁrst consensus guidelines in 1996, this
potential source of inappropriate antibiotic use has
not been evaluated. Whereas treatment for prenatal
urinary tract infection involving GBS is appropriate,
prevention guidelines have consistently advised
against prenatal antibiotics to eradicate GBS coloni-
zation, on the basis of studies showing the failure of
such regimens to lead to successful eradication at the
time of delivery [11,12]. Growing evidence of
adverse neonatal outcomes associated with beta-
lactam regimens given late in pregnancy provides
further reason to avoid this practice [4, 6, 17].
Targeted education of obstetrician-gynecologists
Table I. Factors associated with obstetrician-gynecologists who attempt to eradicate group B streptococcal colonization by prenatal antibiotic
therapy
Factor
Offer antibiotics,
%( n=74)*
Never offer antibiotics,
%( n=260)* OR (95% CI) OR
{ (95% CI)
CARN member 55 55 1.0 (0.6, 1.7) 1.2 (0.7, 2.3)
Male 61 52 1.5 (0.9, 2.5)
Clinical experience in years
§
0–7 20 29
8–14 23 25 1.3 (0.6, 2.8)
15–21 23 26 1.3 (0.6, 2.7)
22 + 35 20 2.5 (1.2, 5.1)
Solo or 2-clinician practice setting 40 27 1.8 (1.0, 3.0)
Urban practice setting 39 28 1.7 (1.0, 2.8)
Prolonged antibiotics for GBS-ve pPROM 49 33 2.0 (1.2, 3.5) 2.4 (1.3, 4.5)
Antibiotics for coryza 58 44 1.8 (1.0, 3.1) 2.0 (1.1, 3.8)
All independent variables were examined. CARN status, sex, clinical experience and results with p50.15 were included. *This
denominator is constant throughout the table, except with prolonged use of antibiotics for pPROM where n=311 (69; 242) and prescription
of antibiotics for the common cold, where n=267 (60; 207).
{Adjusted odds ratios are given for all variables included in the ﬁnal model.
§The overall effect of this variable had a p value of 0.07 in univariate analysis.
Table II. Factors associated with obstetrician-gynecologists who continue antibiotics for more than 7 days for women with pPROM and
negative GBS cultures
Factor 47 days % (n=134)* 47 days % (n=235)* OR (95% CI) OR
{ (95% CI)
CARN member 49 54 0.8 (0.5, 1.2) 0.59 (0.4, 1.0)
Male 66 49 2.1 (1.3, 3.2)
Clinical experience in years
§
0–7 19 30
8–14 24 29 1.2 (0.6, 2.2) 1.0 (0.5, 2.1)
15–21 26 25 1.6 (0.9, 3.1) 1.3 (0.6, 2.6)
22 + 34 17 3.1 (1.6, 5.8) 3.0 (1.5, 6.2)
Non-academic practice setting 93 86 2.3 (1.1, 4.9) 2.7 (1.0, 6.9)
Anti-GBS prenatal antibiotics 30 18 2.0 (1.2, 3.5) 1.9 (1.1, 3.4)
Patient population 475% obstetric 93 89 1.8 (0.3, 1.2)
All independent variables were examined. Results with p50.15 were included in this table. *This denominator is constant throughout the
table, except with the prescription of prenatal antibiotics for colonization where n=311 (113;198).
{Adjusted odds ratios, for all variables
included in the ﬁnal model.
§The overall effect of this variable had a p value of 0.002 in univariate analysis and 0.005 in multivariable analysis.
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chemoprophylaxis to the intrapartum period could
lead to reductions in prenatal antibiotic prescription,
particularly as universal prenatal screening for GBS
becomes widespread. Since providers who pre-
scribed prenatal antibiotics for GBS colonization
were also more likely to prescribe antibiotics for the
common cold, such providers appear to have a
tendency to overuse antibiotics and may need
targeted messages to address these practices.
Because data on the beneﬁts of antibiotics for
pPROM are less clear, ACOG’s guidelines are
more permissive, although a recent practice bulle-
tin published after our survey suggests restricting
antibiotics for pPROM to cases of extreme
prematurity, in order to minimize adverse con-
sequences of antibiotics [19]. Almost all survey
respondents initiated short courses of antibiotics
for pPROM and discontinued therapy within 7
days for GBS-negative women with no signs of
intrapartum infection. Termination of therapy for
GBS-negative women is consistent with GBS
prevention recommendations. Initiation of antibio-
tics for women with pPROM close to term may
not always be indicated, however, and particularly
not for women where the GBS status is known to
be negative at the time of arrival.
Approximately a third of obstetrician-gynecolo-
gists continued antibiotics for more than 7 days for
women with negative GBS cultures without clinical
signs of infection. This extended duration of
therapy does not have empiric support and
represents overuse of antibiotics except in excep-
tional circumstances. Additionally, many included
beta-lactam agents in pPROM regimens although
beta-lactams, and particularly those closely related
to co-amoxiclav, should be used with caution for
GBS-negative women with pPROM in view of
growing evidence for an association between co-
amoxiclav and an increased risk of necrotizing
enterocolitis [17].
Providers prescribing prolonged regimens were
more likely to have extensive years of clinical
practice, suggesting that older providers may have
been more inﬂuenced by earlier studies highlighting
the beneﬁts of antibiotics, particularly before use of
corticosteroids and tocolytics was routine. They also
tended to work in non-academic settings. As
pPROM management recommendations evolve,
outreach to these groups in particular might be
important. Until recommendations can clearly de-
lineate the circumstances where antibiotics are
beneﬁcial for pPROM, decision-making theory
suggests that providers choosing prolonged therapy
for GBS-negative women are likely to continue
current patterns of use [22].
Mistrust of GBS culture results was never the sole
reason for prolonged therapy, although almost a
quarter of respondents listed it as a contributing
factor. As universal GBS screening is implemented,
monitoring of laboratory compliance with specimen
processing recommendations will be important to
maintain clinician conﬁdence in GBS culture results.
This evaluation shares many of the limitations of
survey investigations. The response rate (50%) was
somewhat lower than rates achieved in other surveys
of ACOG Fellows (60 to 70%), although it was
higher than that achieved in a survey of maternal-
fetal medicine specialists on a similar topic [23]. As is
often the case with self-administered surveys, we may
have elicited a biased response due to self-reporting
of practices. In particular, respondents may have
given answers they thought the investigators wanted,
therefore underestimating overuse of antibiotics.
Nonetheless, our survey identiﬁed some important
opportunities to reduce overuse of antibiotics in the
obstetric setting. For perinatal GBS disease preven-
tion, careful adherence to the current prevention
guidelines, which are consistent among the major
professional organizations, will help limit inappropri-
ate antibiotic use. For pPROM, prevention strategies
have not yet been identiﬁed and interventions to
minimize the neonatal morbidity associated with
pPROM require more research. In the meantime,
unnecessary antibiotic use can be avoided by
encouraging physicians to weigh the risks involved
in each case, to administer antibiotics preferentially
in cases of extreme prematurity, and to limit duration
of therapy.
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